Glioblastoma Multiforme: Diagnosis, Treatment, and Invasion

Overview

Journal J Biomed Res

Specialty General Medicine

Date 2022 Nov 20

PMID 36403983

Authors

Jiawei Li

Lili Feng

Yingmei Lu

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is an essentially incurable brain tumor, which has been explored for approximately a century. Nowadays, surgical resection, chemotherapy, and radiation therapy are still the standardized therapeutic options. However, due to the intrinsic invasion and metastasis features and the resistance to chemotherapy, the survival rate of glioblastoma patients remains unsatisfactory. To improve the current situation, much more research is needed to provide comprehensive knowledge of GBM. In this review, we summarize the latest updates on GBM treatment and invasion. Firstly, we review the traditional and emerging therapies that have been used for GBM treatment. Given the limited efficiency of these therapies, we further discuss the role of invasion in GBM recurrence and progression, and present current research progress on the mode and mechanisms of GBM invasion.

Citing Articles

Expression of some circulating microRNAs as predictive biomarkers for prognosis and treatment response in glioblastoma.

Ali E, Ahmed M, Shawki M, El Arab L, Khalifa M, Swellam M Sci Rep. 2025; 15(1):1933.

PMID: 39809835 PMC: 11733229. DOI: 10.1038/s41598-024-83800-x.

Advances in nano-delivery of phytochemicals for glioblastoma treatment.

Ambele M, Maebele L, Mulaudzi T, Kungoane T, Damane B Discov Nano. 2024; 19(1):216.

PMID: 39718730 PMC: 11668727. DOI: 10.1186/s11671-024-04172-9.

6-Gingerol Induced Apoptosis and Cell Cycle Arrest in Glioma Cells via MnSOD and ERK Phosphorylation Modulation.

Lim S, Chen W, Ko H, Su Y, Wu C, Huang F Biomol Ther (Seoul). 2024; 33(1):129-142.

PMID: 39632791 PMC: 11704400. DOI: 10.4062/biomolther.2024.084.

Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma.

Rusak A, Gasior-Glogowska M, Sargenti A, Krzyzak E, Kotowski K, Mrozowska M Pharmacol Rep. 2024; 77(1):210-228.

PMID: 39607670 PMC: 11743419. DOI: 10.1007/s43440-024-00677-3.

Inhibition of CHI3L1 decreases N-cadherin and VCAM-1 levels in glioblastoma.

Rusak A, Gasior-Glogowska M, Sargenti A, Krzyzak E, Kotowski K, Mrozowska M Res Sq. 2024; .

PMID: 39399677 PMC: 11469515. DOI: 10.21203/rs.3.rs-4963939/v1.

References

Rajaratnam V, Islam M, Yang M, Slaby R, Ramirez H, Mirza S . Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers (Basel). 2020; 12(4). PMC: 7226351. DOI: 10.3390/cancers12040937. View

Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

Tilak M, Holborn J, New L, Lalonde J, Jones N . Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. Int J Mol Sci. 2021; 22(4). PMC: 7918566. DOI: 10.3390/ijms22041831. View

Dongre A, Weinberg R . New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2018; 20(2):69-84. DOI: 10.1038/s41580-018-0080-4. View

Fontana R, Ranieri M, La Mantia G, Vivo M . Dual Role of the Alternative Reading Frame ARF Protein in Cancer. Biomolecules. 2019; 9(3). PMC: 6468759. DOI: 10.3390/biom9030087. View

Garcia J, Hurwitz H, Sandler A, Miles D, Coleman R, Deurloo R . Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 2020; 86:102017. DOI: 10.1016/j.ctrv.2020.102017. View

Ma T, Qian K, Xu T, Wang X, Qian T, Shi J . Serpin peptidase inhibitor, clade E nexin group 1 promotes cellular proliferative capacities and malignant behaviors in glioblastoma through upregulating hairy and enhancer of split-1. J BUON. 2021; 26(5):2074-2083. View

Montemurro N, Fanelli G, Scatena C, Ortenzi V, Pasqualetti F, Mazzanti C . Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: A single-center retrospective series. Clin Neurol Neurosurg. 2021; 207:106735. DOI: 10.1016/j.clineuro.2021.106735. View

Ou A, Ott M, Fang D, Heimberger A . The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma. Cancers (Basel). 2021; 13(3). PMC: 7865703. DOI: 10.3390/cancers13030437. View

10.

Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S . Survival Analysis of Glioblastoma Multiforme. Asian Pac J Cancer Prev. 2018; 19(9):2613-2617. PMC: 6249474. DOI: 10.22034/APJCP.2018.19.9.2613. View

11.

Duraj T, Garcia-Romero N, Carrion-Navarro J, Madurga R, Ortiz de Mendivil A, Prat-Acin R . Beyond the Warburg Effect: Oxidative and Glycolytic Phenotypes Coexist within the Metabolic Heterogeneity of Glioblastoma. Cells. 2021; 10(2). PMC: 7922554. DOI: 10.3390/cells10020202. View

12.

Bagherian A, Roudi B, Masoudian N, Mirzaei H . Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib. Food Funct. 2021; 12(21):10926-10937. DOI: 10.1039/d1fo01611c. View

13.

Tejada S, Becerra-Castro M, Nunez-Cordoba J, Diez-Valle R . Ki-67 Proliferative Activity in the Tumor Margins as a Robust Prognosis Factor in Glioblastoma Patients. J Neurol Surg A Cent Eur Neurosurg. 2020; 82(1):53-58. DOI: 10.1055/s-0040-1709730. View

14.

Wen J, Chen W, Zhu Y, Zhang P . Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis. BMC Cancer. 2021; 21(1):81. PMC: 7816395. DOI: 10.1186/s12885-021-07800-0. View

15.

Li R, Wang H, Liang Q, Chen L, Ren J . Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies. Biomater Sci. 2022; 10(4):892-908. DOI: 10.1039/d1bm01401c. View

16.

Sun K, Zhou X, Li T, Zuo M, Li J, Liu Y . Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma. Neurosurg Rev. 2021; 44(6):3335-3348. DOI: 10.1007/s10143-021-01492-7. View

17.

England B, Huang T, Karsy M . Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 2013; 34(4):2063-74. DOI: 10.1007/s13277-013-0871-3. View

18.

Alieva M, Leidgens V, Riemenschneider M, Klein C, Hau P, van Rheenen J . Intravital imaging of glioma border morphology reveals distinctive cellular dynamics and contribution to tumor cell invasion. Sci Rep. 2019; 9(1):2054. PMC: 6375955. DOI: 10.1038/s41598-019-38625-4. View

19.

Du L, Lee J, Jiang H, Wang C, Wang S, Zheng Z . β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 2020; 217(11). PMC: 7596815. DOI: 10.1084/jem.20191115. View

20.

Mousson A, Legrand M, Steffan T, Vauchelles R, Carl P, Gies J . Inhibiting FAK-Paxillin Interaction Reduces Migration and Invadopodia-Mediated Matrix Degradation in Metastatic Melanoma Cells. Cancers (Basel). 2021; 13(8). PMC: 8070677. DOI: 10.3390/cancers13081871. View